Therapeutic Asset Ratings

8,399 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Mesna Hepatoblastoma	St. Jude Children's Research Hospital	P1/2	CCC (52)
Mesna B-Cell Acute Lymphoblastic Leukemia	St. Jude Children's Research Hospital	P1/2	CCC (52)
Mesocella-Ortho Administration Osteoarthritis, Knee	Jagiellonian University	P1/2	CCC (52)
MIDAZOLAM Acute Myeloid Leukemia	Novartis Pharmaceuticals	P1/2	CCC (52)
MONOCLONAL ANTIBODY BC8 Diffuse Large B-Cell Lymphoma	University of Texas Southwestern Medical Center	P1/2	CCC (52)
Navitoclax Refractory Malignant Neoplasm	National Cancer Institute (NCI)	P1/2	CCC (52)
Niraparib Recurrent Fallopian Tube Carcinoma	City of Hope Medical Center	P1/2	CCC (52)
Nivolumab Malignant Pleural Mesothelioma	Memorial Sloan Kettering Cancer Center	P1/2	CCC (52)
Ociperlimab Relapsed/Refractory Diffuse Large B-Cell Lymphoma	BeiGene	P1/2	CCC (52)
Omnipaque Adolescent Obesity	University of Colorado, Denver	P1/2	CCC (52)
Omnipaque Diabetic Kidney Disease	University of Colorado, Denver	P1/2	CCC (52)
Omnipaque Diabetic Kidney Disease	University of Colorado, Denver	P1/2	CCC (52)
Oxodotreotide Esthesioneuroblastoma	National Cancer Institute (NCI)	P1/2	CCC (52)
Oxodotreotide Small Cell Lung Carcinoma	Peking University Cancer Hospital & Institute	P1/2	CCC (52)
Parsaclisib Diffuse Large B-Cell Lymphoma	Incyte Biosciences Japan GK	P1/2	CCC (52)
PE 2I REM Sleep Behavior Disorder	Universitaire Ziekenhuizen KU Leuven	P1/2	CCC (52)
Pembrolizumab Adenoid Cystic Carcinoma	Seagen, a wholly owned subsidiary of Pfizer	P1/2	CCC (52)
Pembrolizumab Lynch Syndrome	Medicenna Therapeutics, Inc.	P1/2	CCC (52)
Pembrolizumab Microsatellite Instability High	NextCure, Inc.	P1/2	CCC (52)
Pepinemab Head And Neck Squamous Cell Carcinoma	Vaccinex Inc.	P1/2	CCC (52)
Pevonedistat Therapy Related Acute Myeloid Leukemia And Myelodysplastic Syndrome	University of Southern California	P1/2	CCC (52)
Polyiclc Locally Advanced Renal Cell Carcinoma	Mayo Clinic	P1/2	CCC (52)
Polyiclc Merkel Cell Carcinoma	University of Southern California	P1/2	CCC (52)
Polypepi1018 Colorectal Cancer	Mayo Clinic	P1/2	CCC (52)
Pomalidomide Cancer	SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany	P1/2	CCC (52)

Showing 626 to 650 of 8,399 assets

PreviousPage 26 of 336Next